BAIT
EPHB4
HTK, MYK1, TYRO11
EPH receptor B4
GO Process (7)
GO Function (3)
GO Component (2)
Gene Ontology Biological Process
Gene Ontology Molecular Function
Gene Ontology Cellular Component
Homo sapiens
PREY
PTPRJ
CD148, DEP1, HPTPeta, R-PTP-ETA, SCC1
protein tyrosine phosphatase, receptor type, J
GO Process (17)
GO Function (9)
GO Component (8)
Gene Ontology Biological Process
- contact inhibition [NAS]
- negative regulation of MAP kinase activity [IDA]
- negative regulation of T cell receptor signaling pathway [IDA, IMP]
- negative regulation of cell growth [IDA]
- negative regulation of cell migration [IDA]
- negative regulation of cell proliferation [IDA]
- negative regulation of epidermal growth factor receptor signaling pathway [IMP]
- negative regulation of platelet-derived growth factor receptor signaling pathway [IDA]
- negative regulation of protein kinase B signaling [IMP]
- negative regulation of vascular permeability [IDA]
- peptidyl-tyrosine dephosphorylation [IDA, IMP]
- platelet-derived growth factor receptor signaling pathway [IMP]
- positive chemotaxis [IDA]
- positive regulation of cell adhesion [IMP]
- positive regulation of focal adhesion assembly [IMP]
- positive regulation of protein kinase B signaling [IMP]
- regulation of cell adhesion [IMP]
Gene Ontology Molecular Function- beta-catenin binding [IPI]
- delta-catenin binding [IPI]
- gamma-catenin binding [IPI]
- mitogen-activated protein kinase binding [IPI]
- phosphatase activity [IDA, IMP]
- platelet-derived growth factor receptor binding [IPI]
- protein binding [IPI]
- protein kinase binding [IPI]
- protein tyrosine phosphatase activity [IDA, IMP]
- beta-catenin binding [IPI]
- delta-catenin binding [IPI]
- gamma-catenin binding [IPI]
- mitogen-activated protein kinase binding [IPI]
- phosphatase activity [IDA, IMP]
- platelet-derived growth factor receptor binding [IPI]
- protein binding [IPI]
- protein kinase binding [IPI]
- protein tyrosine phosphatase activity [IDA, IMP]
Gene Ontology Cellular Component
Homo sapiens
Negative Genetic
Mutations/deletions in separate genes, each of which alone causes a minimal phenotype, but when combined in the same cell results in a more severe fitness defect or lethality under a given condition. This term is reserved for high or low throughput studies with scores.
Publication
Synergistic drug combinations for cancer identified in a CRISPR screen for pairwise genetic interactions.
Identification of effective combination therapies is critical to address the emergence of drug-resistant cancers, but direct screening of all possible drug combinations is infeasible. Here we introduce a CRISPR-based double knockout (CDKO) system that improves the efficiency of combinatorial genetic screening using an effective strategy for cloning and sequencing paired single guide RNA (sgRNA) libraries and a robust statistical scoring ... [more]
Nat. Biotechnol. Mar. 20, 2017; 0(); [Pubmed: 28319085]
Quantitative Score
- -3.614 [Confidence Score]
Throughput
- High Throughput
Ontology Terms
- phenotype: growth abnormality (HP:0001507)
Additional Notes
- CRISPR GI screen
- Cell Line:K562 (EFO:0002067)
- Experimental Setup:Timecourse
- GIST: A-phenotypic negative genetic interaction
- Library:Drug Target-CDKO CRISPRn library
- Significance Threshold: q-value<0.05
Curated By
- BioGRID